Table 3.

Clinical and demographic baseline data of follow-up patients

Age (years)	Gender	Baseline QMG	Baseline MG-ADL	Follow-up QMG	Follow-up MG-ADL	Baseline therapy	Follow-up therapy	Baseline ITIH3 (ng/ml)	Follow-up ITIH3 (ng/ml)	Follow-up time point (months)	Steroids (mg/day)	Responder
43	f	9	11	9	6	MMF	AZA	1592.849	890.391	8	0	Yes
68	m	13	8	13	5	Naïve	MTX	1203.973	832.151	4	5	Yes
54	m	10	25	4	8	Naïve	ECU	561.49	950.29	6	5	Yes
28	f	16	24	12	16	Naïve	EFG	1543.299	748.127	6	5	Yes
54	m	12	7	4	2	RTX	ECU	684.299	291.227	8	0	Yes
62	f	22	30	12	16	Naïve	ECU	1832.291	983.221	6	2.5	Yes
21	f	6	12	7	9	Naïve	AZA	890.829	560.322	6	5	Yes
32	f	12	18	8	12	Naïve	ECU	1993.289	482.991	6	0	Yes
68	m	20	19	2	3	AZA	ECU	1693.289	493.392	6	0	Yes
36	f	10	12	7	6	Naïve	EFG	1294.299	439.29	6	2.5	Yes
66	m	15	4	15	11	Naïve	AZA	792.382	827.382	4	5	No
61	m	2	3	2	3	MMF	AZA	178.299	114.293	4	7,5	no
73	m	10	4	10	3	MMF	AZA	672.407	635.495	4	0	no
37	f	1	3	1	2	Naïve	AZA	359.8676	325.841	4	0	no
31	f	13	11	13	12	Naïve	RTX	625.291	389.211	6	10	no
66	m	2	5	6	5	AZA	ECU	522.832	581.74	4	5	no
32	f	3	8	3	8	Naïve	AZA	798.299	438.128	6	0	no

Individual clinical and demographic data of follow-up patients. MG patients were defined as treatment responders if they improved by ≥ 3 points on the MG-ADL scale. ITIH3 levels were measured in serum samples by ELISA. All patients were anti-AChR-Ab positive

AChR acetylcholine receptor, Ab antibody, AZA azathioprine, ECU eculizumab, EFG efgartigimod, f female, ITIH3 inter-alpha-trypsin inhibitor heavy chain H3, m male, MG-ADL myasthenia gravis activities of daily living, MMF mycophenolate-mofetil, MTX methotrexate, QMG quantitative myasthenia gravis, RTX rituximab